Attached files

file filename
EX-21 - EXHIBIT 21 - BRAINSTORM CELL THERAPEUTICS INC.v403621_ex21.htm
EXCEL - IDEA: XBRL DOCUMENT - BRAINSTORM CELL THERAPEUTICS INC.Financial_Report.xls
EX-31.2 - EXHIBIT 31.2 - BRAINSTORM CELL THERAPEUTICS INC.v403621_ex31-2.htm
EX-32.2 - EXHIBIT 32.2 - BRAINSTORM CELL THERAPEUTICS INC.v403621_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - BRAINSTORM CELL THERAPEUTICS INC.v403621_ex32-1.htm
EX-23.2 - EXHIBIT 23.2 - BRAINSTORM CELL THERAPEUTICS INC.v403621_ex23-2.htm
EX-31.1 - EXHIBIT 31.1 - BRAINSTORM CELL THERAPEUTICS INC.v403621_ex31-1.htm
10-K - FORM 10-K - BRAINSTORM CELL THERAPEUTICS INC.v403621_10k.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference to Registration Statement Nos. 333-131880, 333-168763, 333-175460, 333-182546 and 333-198391 on Form S-8 and Nos. 333-201704 and 333-201705 on Form S-3 of our report dated March 25, 2015, relating to the financial statements of BRAINSTORM CELL THERAPEUTICS INC. (which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Company’s ability to continue as a going concern) appearing in this Annual Report on Form 10-K of BRAINSTORM CELL THERAPEUTICS INC. for the year ended December 31, 2014.

 

/s/ Brightman Almagor Zohar & Co.

 

Brightman Almagor Zohar & Co.

 

Member of Deloitte Touche Tohmatsu Limited

 

Tel Aviv, Israel

 

March 26, 2015